- Previous Close
0.0268 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.1048 - Volume
0 - Avg. Volume
1,216 - Market Cap (intraday)
9.78M - Beta (5Y Monthly) 1.54
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0500 - Earnings Date Apr 14, 2025 - Apr 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Numinus Wellness Inc. provides psychedelic-assisted psychotherapy products and services in Canada and the United States. The company operates through Clinical Research Operations, Canadian Clinic Network, and U.S Clinic Network segments. The Clinical Research Operations segment offers clinical research management services to academic institutions and biotechnology companies. The Canadian Clinic Network segment provides clinical services, including traditional therapy and counseling, ketamine-assisted therapies for depression, psychedelic-assisted therapies, mindfulness programs, and virtual psychotherapy services, as well as neurological care services. The US clinic network segment offers psychedelic-assisted therapies, transcranial magnetic stimulation, and psychiatric and medical model management services. The company also offers laboratory services, such as the cultivation, production, and extraction of natural Psilocybe and other psychoactive fungi species, the development of proprietary processes and products, methods for controlled psychedelics and development of a pipeline for product development, and protocol development and safety and efficacy studies; lab testing services; and psychedelic-assisted therapy training services. The company was incorporated in 1964 and is headquartered in Vancouver, Canada.
www.numinus.com--
Full Time Employees
August 31
Fiscal Year Ends
Sector
Industry
Recent News: LR23.MU
View MorePerformance Overview: LR23.MU
Trailing total returns as of 1/20/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LR23.MU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LR23.MU
View MoreValuation Measures
Market Cap
9.73M
Enterprise Value
12.00M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.49
Price/Book (mrq)
2.75
Enterprise Value/Revenue
0.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-113.22%
Return on Assets (ttm)
-51.49%
Return on Equity (ttm)
-187.91%
Revenue (ttm)
22.48M
Net Income Avi to Common (ttm)
-25.51M
Diluted EPS (ttm)
-0.0500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.7M
Total Debt/Equity (mrq)
152.76%
Levered Free Cash Flow (ttm)
-8.22M